Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
J Oldgren, A Budaj, CB Granger, Y Khder… - European heart …, 2011 - academic.oup.com
Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a …
Aims After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety
and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of …
and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of …
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials
K Uchino, AV Hernandez - Archives of internal medicine, 2012 - jamanetwork.com
Background The original RE-LY (Randomized Evaluation of Long-term Anticoagulant
Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of …
Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of …
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
Background—The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY)
trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 …
trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 …
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind …
Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard
antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor …
antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor …
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all‐cause mortality: a systematic review and meta‐analysis of …
Background Signals of an increased risk of myocardial infarction (MI) have been identified
with dabigatran etexilate in randomized controlled trials (RCTs). Methods and Resules We …
with dabigatran etexilate in randomized controlled trials (RCTs). Methods and Resules We …
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an …
DA Gorog, JL Ferreiro, I Ahrens, J Ako… - Nature Reviews …, 2023 - nature.com
Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …
[HTML][HTML] Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Background Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the
standard of care after percutaneous coronary intervention (PCI) for patients with atrial …
standard of care after percutaneous coronary intervention (PCI) for patients with atrial …
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
Abstract Aims Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant
ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …
ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …
De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes
S Shoji, T Kuno, T Fujisaki, H Takagi… - Journal of the American …, 2021 - jacc.org
Background Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …
相关搜索
- antiplatelet therapy placebo in patients
- antiplatelet therapy dabigatran or warfarin
- antiplatelet therapy randomized evaluation
- antiplatelet therapy coronary thrombosis
- antiplatelet therapy platelet inhibition
- randomized evaluation dabigatran or warfarin
- antiplatelet therapy concomitant use
- antiplatelet therapy expert panel
- antiplatelet therapy consensus statement
- anticoagulation therapy dabigatran or warfarin
- anticoagulation therapy randomized evaluation